Trevi Therapeutics, Inc. (TRVI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.21: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.50; Below-average business quality.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.... Read more
Sell if holding. Engine safety override at $14.21: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-14Recent Developments — Trevi Therapeutics, Inc.
Latest news
- NEWS Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target — benzinga May 20, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target — benzinga May 6, 2026 positive
- NEWS Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23 — benzinga May 6, 2026 neutral
- NEWS Trevi Therapeutics Q1 2026 Earnings Call Transcript — benzinga May 5, 2026 neutral
- NEWS Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate — benzinga May 5, 2026 negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.21: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.22. Score 5.5/10, moderate confidence.
Take-profit target: $20.79 (+46.3% upside). Prior stop was $13.22. Stop-loss: $13.22.
Quality below floor (1.5 < 4.0).
Trevi Therapeutics, Inc. trades at a P/E of N/A (forward -25.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover TRVI with a consensus score of 4.3/5. Average price target: $24.
What does Trevi Therapeutics, Inc. do?Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational...
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.